

ESMO Advanced Course on Clinical Questions in Prostate Cancer

Programme

SINGAPORE

6-7 SEPTEMBER 2019

Co-Chairs

Karim Fizazi, FR

Ravindran Kanesvaran, SG

ESMO ADVANCED COURSE PROGRAMME CLINICAL QUESTIONS IN PROSTATE CANCER

Singapore
6-7 September 2019

CO-CHAIRS: Karim Fizazi, France
Ravindran Kanesvaran, Singapore

SPEAKERS: Arun Azad, Australia
Melvin L. K. Chua, Singapore
Jin Wei Kwek, Singapore
David Olmos Hidalgo, Spain
Darren M. C. Poon, Hong Kong

LEARNING OBJECTIVES

- To understand essentials in the assessment and the value of multidisciplinary management of prostate cancer
- To learn about state-of-the-art advances in treatment of prostate cancer
- To learn the principles of management of advanced prostate cancer through direct exposure to real clinical scenarios

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 6 September 2019

09:00-09:20 20'	Welcome and course overview Karim Fizazi, FR Ravindran Kanesvaran, SG
09:20-10:35	Session 1 State-of-the-art in prostate cancer diagnostics
20'	Updates in imaging Jin Wei Kwek, SG
20'	PSA screening Ravindran Kanesvaran, SG
20'	Biology: How cancer genetics can impact on clinical decision making? David Olmos Hidalgo, ES
15'	Discussion Faculty
10:35-11:00	<i>Coffee break</i>
11:00-12:05	Session 2 High risk localized prostate cancer
25'	Role of radiotherapy: Recent advances in RT modalities Melvin L. K. Chua, SG
25'	High risk localized disease: Integrating drugs with local treatments Darren M. C. Poon, HK
15'	Discussion Faculty
12:05-13:00	<i>Lunch</i>
13:00-14:15	Session 3 Intermediate situation of advanced prostate cancer
20'	Rising PSA: What to do? Darren M. C. Poon, HK
20'	Oligometastatic prostate cancer Melvin L. K. Chua, SG
20'	M0 Castrate Resistant Prostate Cancer (CRPC): What are our latest options? Arun Azad, AU
15'	Discussion Faculty
14:15-15:50	Session 4 Metastatic prostate cancer
20'	Metastatic hormone sensitive prostate cancer: State-of-the-art management in 2019 Ravindran Kanesvaran, SG
20'	Metastatic CRPC: Standard of care in 2019 Arun Azad, AU

Session 4 - cont.
Metastatic prostate cancer

- 20' Metastatic CRPC: What's on the horizon - new treatments (PARP inhibitors, immunotherapy)?
Karim Fizazi, FR
- 15' ESMO Magnitude of Clinical Benefit Scale
Ravindran Kanesvaran, SG
- 20' Discussion and summary
Karim Fizazi, FR
Ravindran Kanesvaran, SG
- 15:50-16:20 *Coffee break*
- 16:20-17:00 **Tour of NCCS premises**
- 19:00 *Networking dinner*

Saturday, 7 September 2019

- 09:00-12:30 **Workshop sessions**
Three parallel workshop sessions with around 20 delegates in each group (delegates will attend all 3 sessions on a rotation basis)
15' Introduction based on clinical cases presented by speakers
40' Discussion
5' Break
- Workshop 1** **Localized prostate cancer**
60' Melvin L. K. Chua, SG
Darren M. C. Poon, HK
- Workshop 2** **Intermediate advanced prostate cancer**
60' Arun Azad, AU
Ravindran Kanesvaran, SG
- Workshop 3** **Metastatic prostate cancer**
60' Karim Fizazi, FR
David Olmos Hidalgo, ES
- 11:00-11:30 *Coffee break*
- 11:30-12:30 **Workshops 1-2-3 continuation**
- 12:30-13:00 **Feedback on the workshops from each group**
- 13:00-13:15 **Synthesis and wrap-up**
15' Karim Fizazi, FR
Ravindran Kanesvaran, SG
- 13:15-14:15 *Lunch*